BioSpace News Archive

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma.

AVITA Medical, Inc. invites shareholders and prospective investors to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on September 20, 2022 at 3:30pm / September 21, 2022 at 8:30am.

The latest market analysis report published by Reports and Data, titled ‘Global Bulimia Nervosa Treatment Market – Forecast to 2030,’ thoroughly examines the Bulimia Nervosa Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Biliary Tumor Market – Forecast to 2030,’ thoroughly examines the Biliary Tumor industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Bladder Pain Treatment Market – Forecast to 2030,’ thoroughly examines the Bladder Pain Treatment industry to provide essential data & information for the targeted readers.

Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Company’s Actera™ Hip System.

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 197,200 shares of its common stock to 10 employees outside Fusion’s 2020 Stock Option and Incentive Plan.

InMed Pharmaceuticals Inc. announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share priced at-the-market under Nasdaq rules.

The latest market analysis report published by Reports and Data, titled ‘Global Cholestasis Pruritus Treatment Market – Forecast to 2030,’ thoroughly examines the Cholestasis Pruritus Treatment industry to provide essential data & information for the targeted readers.